Cannabinoid Analogs Cancer Treatment Patent Application

USPTO published patent application US20260097049A1 disclosing hexahydrocannabinol (HHC), hexahydrocannabidivarin (H4CBDV), and hexahydrocannabidivarin (H4CBDV) derivatives along with pharmaceutical compositions containing these compounds. The application claims methods of using these derivatives for treatment and prevention of cancer, specifically identifying pancreatic cancer and lung cancer as target indications.

Affected parties including pharmaceutical companies developing cannabinoid-based therapeutics, oncology drug developers, and potential licensees should monitor this application. If granted, it could establish patent protection for hexahydrocannabinol derivative compositions in cancer treatment applications. Competitors working with HHC, H4CBD, or H4CBDV compounds for oncology indications may need to conduct freedom-to-operate analyses or seek licensing arrangements.